Adaptimmune rises as partner takes up option on NY-ESO T-cell therapy
UK headquartered biotech firm Adaptimmune Therapeutics’ (Nasdaq: ADAP) shares were up 11.57% at $7.52 mid-morning today on the news that GlaxoSmithKline (LSE: GSK) has exercised its option to exclusively research, develop and commercialize its NY-ESO SPEAR T-cell therapy. GSK edged up 0.35% to £15.11.
On the exercise of this option and transition of the program, UK pharma major GSK will assume responsibility for all development, manufacturing and commercialization activities for the asset.
Adaptimmune and GSK announced a strategic collaboration and licensing agreement in June 2014 for up to five programs, including the lead NY-ESO TCR program (GSK3377794). In 2015, GSK divested its oncology assets in a swap with Novartis, but said it would continue R&D activity in the oncology arena though not necessarily commercialize resultant products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze